2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2512

Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2790

Selective Disruption of Estrogen Receptor Alpha Expression in Dendritic Cells of Lupus-Prone Mice Results in Increased Female-Specific Death

Systemic Lupus Erythematosus – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 15L

Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis vulgaris and Normalizes Skin Pathology Via Concurrent Regulation of IL-17 and IL-10 Levels

ACR Late-Breaking Poster Session

9:00AM-11:00AM: Abstract Number: 2201

Self-Reported Breathlessness on Exertion Is Associated with Poor Outcomes Among Women with Systemic Lupus Erythematosus (SLE)

Epidemiology and Public Health - ARHP Poster

9:00AM-11:00AM: Abstract Number: 2203

Self-Reported Childhood Maltreatment and Traumatic Events Among Israeli Patients Suffering from Fibromyalgia and Rheumatoid Arthritis

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

9:00AM-11:00AM: Abstract Number: 2754

Self-Reported Physical Activity Questionnaire in Axial Spondyloarthritis: Modification of the Squash

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2942

Sequencing of 16S rRNA Reveals a Distinct Salivary Microbiome Signature in Behcet’s Disease

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2629

Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2612

Sero-Positivity for Rheumatoid Factor Is an Independent Predictor for Achievement of Good EULAR Response at 24 Weeks in ACPA Positive Rheumatoid Arthritis Patients Treated with Abatacept: Results from Japanese Multicenter Registry

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2613

Seropositivity for RF or ACPA Predicts Long Term Drug Retention with Rituximab, but Not with Abatacept and Tocilizumab : Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2506

Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2822

Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2856

Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2328

Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis

Muscle Biology, Myositis and Myopathies - Poster II: Clinical

9:00AM-11:00AM: Abstract Number: 2907

Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].